Dihydroergotamine Mesylate Nasal Spray, Metered
Product Images NDC 69097-503

7 FDA label images from Cipla Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Dihydroergotamine Mesylate Nasal (NDC 69097-503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Imagestructure)

Structure (Imagestructure)
Chemical structure of Dihydroergotamine Mesylate, showing its molecular arrangement. The diagram includes the molecular formula C33H37N5O5•CH4O3S and the molecular weight of 679.78, illustrating the composition of this active ingredient.*
FDA Label Image

Image1 (Graph1)

Image1 (Graph1)
A line graph showing the estimated probability of patients responding within four hours after a single 2 mg dose of Dihydroergotamine mesylate nasal spray compared to placebo. The x-axis represents time from the first dose in hours, and the y-axis shows the probability of response to study medication in percentage. The graph includes two lines representing the nasal spray and placebo over time.*
FDA Label Image

Image2 (Graph2)

Image2 (Graph2)
A line graph titled 'Estimated Probability of a Patient Responding to Dihydroergotamine Mesylate Nasal Spray During the Four Hours Following Dosing' compares response probabilities over 4 hours between Dihydroergotamine mesylate nasal spray and placebo. The X-axis shows time from first dose in hours, and the Y-axis shows estimated probability of response in percent. The nasal spray shows increasing response probability over time compared to placebo.*
FDA Label Image

Image3 (Graph3)

Image3 (Graph3)
A line graph showing the estimated probability over 24 hours of patients using additional migraine treatments after receiving either dihydroergotamine mesylate nasal spray 2 mg or placebo. The x-axis represents hours after the first spray, and the y-axis shows the estimated probability of additional treatment use. The graph compares two curves, with placebo showing a higher probability consistently than dihydroergotamine mesylate nasal spray.*
FDA Label Image

Cipla-vial-label (Viallabel)

Cipla-vial-label (Viallabel)
Label for Dihydroergotamine Mesylate Nasal spray, metered dose, 4 mg/mL strength. The label states it is for nasal use only, not for injection. It includes the NDC 69097-503-31 and identifies Cipla USA Inc. as the labeler located in Warren, NJ. The label also mentions the manufacturer, Mipharm S.p.A., Milan, Italy.*
FDA Label Image

Cipla-inner-carton-label (Innercarton)

Cipla-inner-carton-label (Innercarton)
Packaging label for Dihydroergotamine Mesylate Nasal Spray, 4 mg/mL, metered nasal spray by Cipla USA Inc. The label indicates the product contains 1 vial and 1 sprayer, is for nasal use only, and not for individual sale or injection. Additional instructions include storage below 25°C and reference to migraine therapy administration guidelines.*
FDA Label Image

Cipla-outer-carton-label (Outercarton)

Cipla-outer-carton-label (Outercarton)
Packaging label for Dihydroergotamine Mesylate Nasal Spray 4 mg/mL by Cipla USA Inc. The label states this is a metered nasal spray intended for nasal use only, not for injection. Key ingredients and NDC number 69097-503 are visible along with instructions indicating prescription use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.